A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of ...

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may ...

Panelists discuss how type 2 inflammatory diseases can lead to potential long-term complications or comorbidities, including airway remodeling in asthma, nasal polyps in chronic rhinosinusitis, skin ...

A systematic review analyzing sleep quality and the impact of zinc supplements reveals glaring gaps in knowledge in this area ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

The Heart Failure Society of America (HFSA) annual meeting 2024 was scheduled to showcase groundbreaking research on the ...

At the CHEST 2024 annual meeting, international respiratory society leaders highlighted the need for global collaboration to ...

CMS actuaries foresee a gradual rise in per capita health spending, slowing initially but eventually outpacing economic ...

Hope is on the horizon for patients living with chronic obstructive pulmonary disease (COPD). CHEST 2024 in Boston featured a session highlighting emerging bronchoscopic therapies.

New data presented at CHEST 2024 in Boston revealed a significant link between obstructive sleep apnea and mental health disorders in middle-aged and older adults.

Recent results from a new diabetes reversal program demonstrate the reliable, sustained benefits of nonpharmacological interventions in the management of diabetes and overall health of patients.